Risk StewardRisk Steward
NOTES ON HEALTH, MONEY & A CHANGING WORLDPERSONAL PERSPECTIVES · MALAYSIA

A JOURNAL OF PERSPECTIVE

A changing world.
A judgement
of your own.

Progress gives us possibilities.
Perspective helps us choose.

Notes on health, money and the future—exploring what is changing, what we may have overlooked, and what it could mean for our lives.

TURN THE PERSPECTIVE

If we can detect more, what should we do differently?
Beh Risk Steward THE PERSON BEHIND THE PERSPECTIVE ↗

In focus

Fresh questions. Considered perspectives.

A NOTE FROM THE EDITOR

“I’m interested in a brighter future.
And the questions that help us prepare for it.”

Hope and preparation belong in the same conversation. This journal makes room for both.

A little more about Risk Steward ↗
Journal / Perspective

Money & Legacy

Moderna’s cancer vaccine: what sent the shares up 177%?

On 19 August, Moderna shares closed 177% higher after Moderna and Merck announced that their melanoma trial had met its main goal. That means US$100 in shares at the previous close was worth about US$277 at the next one. Investors had made that move before the detailed results came out in October. What did patients actually gain?

A researcher examines an unlabelled vial.
AI-generated editorial illustration.

Start with who was in the trial. These patients had already had their melanoma removed. The worry after surgery was that it might come back. Researchers tested whether adding an experimental vaccine, tailored to each patient’s tumour, to the immunotherapy drug Keytruda could help more people stay free of cancer. Both groups received Keytruda.

The headline figure was a 42% lower relative risk of recurrence or death over the follow-up period. I find the two-year results easier to picture. For every 100 patients, an estimated 82 were alive without recurrence with the combination, compared with 70 with Keytruda alone. That’s about 12 more people in every 100 reaching two years without the cancer returning. Researchers are still following patients to learn whether they live longer overall.

Melanoma trial results and Moderna share prices in 2026.
Phase 3 trial results and Moderna closing prices in US dollars, 2026.

If a relative sent me that headline after surgery, I’d suggest they ask their specialist, “How closely does this group resemble me, and what options are open to me now?” Learning that a treatment helped people in a trial gives a family reason for hope. Knowing whether it fits their own situation gives them something they can act on.

For an investor, the starting point is different. On 6 November, Moderna raised its revenue outlook on stronger overseas demand for its COVID vaccine. Its shares closed at US$269 on 9 November and US$248.69 two days later. The cancer trial result was the same on both days. The price someone had to pay for a share had changed by more than US$20.

I can be optimistic about the medicine and still take my time over the shares. Before buying, I’d want to know what the price already assumes about approval, how many patients could receive a personalised treatment and what it would cost to make one for each of them.

Trial results · August market reaction · November closing prices · November earnings · Two-year results in plain language

A QUESTION TO CARRY FORWARD

Original article ↗